IONS Ionis Pharmaceuticals Inc
Price (delayed)
$31.4
Market cap
$4.96B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.44
Enterprise value
$6.07B
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and
Highlights
The company's equity has surged by 151% QoQ and by 110% YoY
IONS's quick ratio is up by 40% year-on-year and by 19% since the previous quarter
Key stats
What are the main financial stats of IONS
Market
Valuations
Earnings
Shares outstanding
157.9M
Market cap
$4.96B
Enterprise value
$6.07B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.93
Price to sales (P/S)
5.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.56
Revenue
$803.07M
Gross profit
$792.62M
Operating income
-$370.38M
Net income
-$358.81M
EBIT
-$265.8M
EBITDA
-$243.47M
Free cash flow
-$370.89M
Per share
Balance sheet
Liquidity
EPS
-$2.44
EPS diluted
-$2.44
Free cash flow per share
-$2.5
Book value per share
$4.53
Revenue per share
$5.4
TBVPS
$20.74
Total assets
$3.08B
Total liabilities
$2.42B
Debt
$1.45B
Equity
$662.47M
Working capital
$2.41B
Debt to equity
2.18
Current ratio
8.91
Quick ratio
8.21
Net debt/EBITDA
-4.57
Margins
Efficiency
Dividend
EBITDA margin
-30.3%
Gross margin
98.7%
Net margin
-44.7%
Operating margin
-46.1%
Return on assets
-12.5%
Return on equity
-89.2%
Return on invested capital
-7.3%
Return on capital employed
-9.6%
Return on sales
-33.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IONS stock price
How has the Ionis Pharmaceuticals stock price performed over time
Intraday
-3.77%
1 week
-1.57%
1 month
-10.21%
1 year
-36.62%
YTD
-10.18%
QTD
-10.18%
Financial performance
How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$803.07M
Gross profit
$792.62M
Operating income
-$370.38M
Net income
-$358.81M
Gross margin
98.7%
Net margin
-44.7%
The operating margin is up by 49% year-on-year but it has declined by 2.7% since the previous quarter
The company's net margin rose by 33% YoY
IONS's operating income is up by 33% year-on-year
The gross profit is up by 31% year-on-year
Growth
What is Ionis Pharmaceuticals's growth rate over time
Valuation
What is Ionis Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.93
P/S
5.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.56
Ionis Pharmaceuticals's EPS has increased by 15% YoY and by 3.2% QoQ
The company's equity has surged by 151% QoQ and by 110% YoY
The stock's price to book (P/B) is 63% less than its last 4 quarters average of 18.8 and 39% less than its 5-year quarterly average of 11.3
IONS's revenue is up by 31% YoY
The P/S is 30% less than the last 4 quarters average of 8.3 and 28% less than the 5-year quarterly average of 8.1
Efficiency
How efficient is Ionis Pharmaceuticals business performance
Ionis Pharmaceuticals's return on sales has increased by 35% YoY but it has decreased by 2.2% QoQ
IONS's return on equity is up by 23% since the previous quarter
Ionis Pharmaceuticals's ROIC has increased by 17% YoY
IONS's return on assets is up by 14% year-on-year and by 3.1% since the previous quarter
Dividends
What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IONS.
Financial health
How did Ionis Pharmaceuticals financials performed over time
The total assets is 27% greater than the total liabilities
IONS's quick ratio is up by 40% year-on-year and by 19% since the previous quarter
The current ratio rose by 39% year-on-year and by 17% since the previous quarter
The company's debt is 118% higher than its equity
The company's equity has surged by 151% QoQ and by 110% YoY
Ionis Pharmaceuticals's debt to equity has plunged by 60% from the previous quarter and by 53% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.